Strides Arcolab arm in JV with Pfenex for biosimilar drugs

Strides Arcolab’s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney
moneycontrol.com

Home » News » Business

Apr 17, 2013, 01.28 PM | Source: CNBC-TV18

Strides Arcolab arm in JV with Pfenex for biosimilar drugs

Strides Arcolab’s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

Like this story, share it with millions of investors on M3

Strides Arcolab arm in JV with Pfenex for biosimilar drugs

Strides Arcolab’s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

Post Your Comments

Share Cancel

Markets and Macros

Excerpts from Markets and Macros on CNBC-TV18 Watch the full show »

Strides Arcolab ’s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market and the first product would be launched in 2015 or 2016,  Anand Iyer, CEO, Biotech-Strides Arcolab told CNBC-TV18.

Agila Biotech is 51% equity stake holder in the joint venture, however both parties will equally share decision making for product development and commercialization.

Also read: Contraceptives basket can fetch $150m from US sales: Lupin

The lead product for joint venture Interferon beta-1b, a biosimilar to Betaseron, indicated for relapsing, remitting and secondary-progressive forms of multiple sclerosis and the product will commence human clinical trials by Q4

Iyer denied making any comments on the investment being envisaged by Strides Arcolab in joint venture. He said that the products will be manufactured at its upcoming Malaysian facility.

Below is the verbatim transcript of the interview

Q: First tell us how much money you guys are putting in into this and what does this mean in terms of business? How many products does it already have or will have?

A: I cannot at this point give you an exact figure as to how much money we will be investing. What we can tell you is that the way we have structured the joint venture is there are two parts to this agreement. There is an early joint development and licensing agreement under which we will be jointly developing six products. Many of these products are already in late stages of development. We will then manufacture, and conduct clinical trials out of our Malaysian manufacturing facility which is due to go on-stream at the end of 2014.

Q: So could you tell us how much and how soon could this be monetized? Could you quantify the monetization as well as the timeline?

A: I cannot quantify the monetization at this point in time. What I can tell you is that the first product we will be able to launch sometime in 2015 or 2016, because it depends on the clinical trial. As you know all the biotech products have to undergo clinical trials. Our plan is to do clinical trials in India, Malaysia where we are establishing a research and development and a manufacturing facility and also in few other emerging market countries simultaneously.

Buy, Hold, Sell ? Hear it first on M3
Strides Arcolab arm in JV with Pfenex for biosimilar drugs

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login